[
    [
        {
            "time": "2023-10-10",
            "original_text": "AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI速) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Risankizumab",
                    "SKYRIZI",
                    "Psoriatic Arthritis",
                    "EADV Congress"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI速) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "AbbVie Presents New Analyses Evaluating RINVOQ速 (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress",
            "features": {
                "keywords": [
                    "AbbVie",
                    "RINVOQ",
                    "upadacitinib",
                    "Atopic Dermatitis",
                    "EADV Virtual Congress"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Presents New Analyses Evaluating RINVOQ速 (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]